Jounce Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Jounce Therapeutics generated cash of -$28,877,000, which is more than the previous year. Cash used in financing activities reached the amount of $442,000 last year. Net change in cash is therefore $55,043,000.
Cash Flow
| 2014 | -14.90M | -709K | 15.00M |
|---|---|---|---|
| 2015 | -25.73M | -2.14M | 70.70M |
| 2016 | 179.68M | -215.50M | 35.50M |
| 2017 | -90.73M | -38.02M | 107.47M |
| 2018 | -63.61M | 86.41M | 1.54M |
| 2019 | -30.12M | 31.38M | 4.08M |
| 2020 | -27.78M | 51.29M | 70.74M |
| 2021 | -83.49M | -60.51M | 92.04M |
| 2022 | -28.87M | 83.47M | 442K |
JNCE Cash Flow Statement (2014 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 96.79M | 148.76M | 54.51M | 49.17M | 24.82M | 44.84M | 45.16M | 2.33M | 2.95M |
Operating activities | |||||||||
Net income | -50.91M | -90.87M | -43.84M | 56.82M | -27.37M | -16.44M | -13.70M | -28.53M | -10.51M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||||
Depreciation and amortization | 2.08M | 2.82M | 3.40M | 3.85M | 3.83M | 4.42M | 1.94M | 1.47M | 1.10M |
Stock-based compensation expense | 10.27M | 11.47M | 9.77M | 9.60M | 9.40M | 4.77M | 4.98M | 1.35M | 332K |
| Deferred income tax benefit | 10.27M | 11.47M | 9.77M | 9.60M | 9.40M | 4.77M | 4.98M | 1.35M | 332K |
| Changes in operating assets and liabilities: | |||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 421K | -329K | -296K | -944K | 562K | 373K | -312K | 673K | -301K |
Cash generated by operating activities | -28.87M | -83.49M | -27.78M | -30.12M | -63.61M | -90.73M | 179.68M | -25.73M | -14.90M |
Investing activities | |||||||||
Purchases Of Investments | -24.92M | -130.27M | -85.89M | -188.99M | -252.91M | -179.87M | -213.28M | 0 | 0 |
Investments In Property Plant And Equipment | -919K | -373K | -94K | -985K | -1.35M | -15.10M | -2.22M | -2.20M | -699K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 83.47M | -60.51M | 51.29M | 31.38M | 86.41M | -38.02M | -215.50M | -2.14M | -709K |
Financing activities | |||||||||
Common Stock Issued | 442K | 90.82M | 70.14M | 3.64M | 0 | 107.00M | 50K | 112K | 22K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 55.73M | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 442K | 92.04M | 70.74M | 4.08M | 1.54M | 107.47M | 35.50M | 70.70M | 15.00M |
Net Change In Cash | 55.04M | -51.96M | 94.25M | 5.33M | 24.34M | -21.28M | -313K | 42.82M | -612K |
Cash at end of period | 151.84M | 96.79M | 148.76M | 54.51M | 49.17M | 23.55M | 44.84M | 45.16M | 2.33M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source |